Introduction VZV is closely related to the herpes simplex viruses(HSV), sharing much genomehomology. The known envelope glycoproteins (gB, gC, gE, gH, gI, gK, gL) correspond with those in HSV, however there is no equivalent of HSV gD. VZV virons are spherical and 150-200 nm in diameter. Their lipidenvelope encloses the nucleocapsid of 162 capsomeres arranged in a hexagonalform. Its DNAis a single, linear, double-stranded molecule, 125,000 nt long. The virus is very susceptible to disinfectants, notably sodium hypochlorite. Within the body it can be treated by a number of drugs and therapeutic agents including aciclovir, zoster-immune globulin(ZIG), and vidarabine. 

Description  The E.Coli derived recombinant protein contains the VZV gE immunodominant regions, amino acids 48-135 and fused to a GST-Tag at C-terminus. 

Purification Method  Varicella was purified by proprietary chromatographic technique. 

Purity  Varicella protein is >95% pure as determined by 10% PAGE (coomassie staining). 

Formulation 25mM Tris-Hcl pH 8.0, 1mM EDTA and 50% glycerol. 

Storage  Varicella Protein although stable at 4°C for 1 week, should be stored below -18°C.

Please prevent freeze thaw cycles. 

Specificity  Immunoreactive with sera of VZV-infected individuals. 

Applications  Varicella Zoster antigen is suitable for ELISA and Western blots, excellent antigen for detection of VZV with minimal specificity problems.